RequestUpdated on 26 June 2025
Developing novel immune modulators for improved outcomes in cancer therapy
About
Abbmira is a Swiss biotech startup open to collaboration with academics, clinicians and companies in the field of preclinical R&D in drug-development, in particular in the area of immuno-oncology.
Organisation
Similar opportunities
Expertise
Preclinical Immuno-Modulatory Drug Development in Oncology
- CHE - Chemistry
- LIF - Life Sciences
- DOCTORAL NETWORKS: Hosting Doctoral Candidates / Secondments / Trainings
- POSTDOCTORAL FELLOWSHIPS: Hosting Postdoctoral Candidates / Secondments / Placements
Marc Creus
CEO at abbmira therapeutics AG
Basel, Switzerland
Project cooperation
Preclinical Immuno-modulatory Drug Development in Oncology
- MSCA-PF2025
- MSCA-DN2025
- Proposal Idea
- Proposal under Development
- POSTDOCTORAL FELLOWSHIP: Looking for an Institution for Secondment
- DOCTORAL NETWORK: Looking for Partner/s (Beneficiaries or Associated Partners)
Marc Creus
CEO at abbmira therapeutics AG
Basel, Switzerland
Request
Michael Chen
Professor, Chair of Therapeutic Engineering at The University of Edinburgh
Edinburgh, United Kingdom